Floatz logo

pt-112

mCRPC

Promontory Therapeutics Inc.Phase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

7 Active assets in the mCRPC cohort.

Asset / SponsorPhaseRating
Tislelizumab
Shanghai Changzheng Hospital
Phase 2B
IMIFOPLATIN
Promontory Therapeutics Inc.
Phase 2CCC
Inkmune
Inmune Bio, Inc.
Phase 1/2CCC
Tyk-00540
TYK Medicines, Inc
Phase 1/2CC
Ktx-2001
K36 Therapeutics, Inc.
Phase 1CC
[177lu]lu-psma-xt
Jinming Zhang
Phase 1CC
IBI311
Shanghai Changzheng Hospital
Early Phase 1C
rg1507
Shanghai Changzheng Hospital
Early Phase 1C

Same molecule, other indications

pt-112 is also rated in:

CRPCDormant
CCC
Indicative ·
53 / 100
View asset →
Metastatic Castrate-resistant Prostate CancerDormant
CCC
Indicative ·
53 / 100
View asset →
PT-112Dormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →